ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 869 • 2013 ACR/ARHP Annual Meeting

    Anti-Carbamylated Protein Antibodies Are Present Prior To The Diagnosis Of Rheumatoid Arthritis and Predict Future Disease Onset

    Ryan W. Gan1, Leendert A. Trouw2, Jing Shi2, René E.M. Toes2, Tom W. J. Huizinga2, Gary O. Zerbe3, Kevin D. Deane4, Jess Edison5, William R. Gilliland6, Jill M. Norris1 and V. Michael Holers7, 1Epidemiology, Colorado School of Public Health, Aurora, CO, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 4Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 5Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 6Walter Reed National Military Medical Center, Bethesda, MD, 7Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Anti-cyclic citrullinated peptide-2 (CCP2) can be present in serum years before a diagnosis of rheumatoid arthritis (RA), and is highly specific (>95%) for the…
  • Abstract Number: 870 • 2013 ACR/ARHP Annual Meeting

    How To Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According To ACR/EULAR 2010 After a 3-Years Follow-Up? Results From The Espoir Cohort

    Gaël Mouterde1, Cédric Lukas2, Nathalie Rincheval3, Alain Saraux4, Philippe Dieude5 and Bernard Combe6, 1Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, 2Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 3Institut Universitaire de Recherche Clinique, Montpellier, France, 4Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, 5Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, 6Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France

    Background/Purpose: To describe disease course of patients without rheumatoid factor (RF) and anti-citrullinated protein auto-antibodies (ACPA) in an inception cohort of early arthritis patients. To determine…
  • Abstract Number: 871 • 2013 ACR/ARHP Annual Meeting

    Do We Need To Lower The Cut Point Of The 2010 ACR/EULAR Classification Criteria For Diagnosing Rheumatoid Arthritis?!

    M. van der Ven1, J.J. Luime1, A.H. Gerards2, C. Alves1, P.J. Barendregt3, D. van Zeben4, M.H. de Jager5, P.B.J. de Sonnaville6, B.A. Grillet7 and J.M.W. Hazes1, 1Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 3Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 4Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, 6Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 7Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) were recently developed to facilitate the study of persons at earlier stages of the disease.…
  • Abstract Number: 872 • 2013 ACR/ARHP Annual Meeting

    Spontaneous Remission In Patients Fulfilling The 2010 Classification Criteria For Rheumatoid Arthritis: The Impact Of Duration Of Joint Swelling

    Ellen Sauar Norli1, Elisabeth Lie2, Gina Hetland Brinkmann3, Olav Bjørneboe4, Halvor Nygaard5, Anne Julsrud Haugen3, Patrik Stolt6, Cathrine Thunem7, Tore K. Kvien2 and Maria Mjaavatten2, 1Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, 4Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, 5Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, 6Dept. of Rheumatology, Innlandet Hospital Trust, Brumunddal, Norway, 7Dept. of Rheumatology, Betanien Hospital, Skien, Norway

    Background/Purpose: In 2010 the new ACR/EULAR classification criteria for rheumatoid arthritis (RA criteria) were published. The prospects for early diagnosis and treatment have increased over…
  • Abstract Number: 873 • 2013 ACR/ARHP Annual Meeting

    Health Fair Evaluations To Identify Subjects At-Risk For Future Inflammatory Arthritis and Rheumatoid Arthritis

    Kristen E. Beck1, M. Kristen Demoruelle2, Christopher C. Striebich3, Kaylynn Aiona4, Marie L. Feser2, Lezlie A. Derber5, Stacey Brake6, Jill Lysengen7, Laura Rosseisen7, Julia J. Rhiannon8, Stuart M. Weisman5, Jill M. Norris9, V. Michael Holers10 and Kevin D. Deane2, 1University of Colorado School of Medicine, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3University of Colorado Denver, Aurora, CO, 4Colorado School of Public Health, Aurora, CO, 5University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, 69Health Fair, Denver, CO, 7Arthritis Foundation, Great West Region, Denver Office, Denver, CO, 8Rheumatology, University of Colorado School of Medicine, Aurora, CO, 9Epidemiology, Colorado School of Public Health, Aurora, CO, 10Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Multiple studies demonstrate that there is a preclinical period of rheumatoid arthritis (RA) when autoantibodies (Abs) including RF and anti-CCP are abnormal in absence…
  • Abstract Number: 874 • 2013 ACR/ARHP Annual Meeting

    Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy:  Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

    Clifton O. Bingham III1, Rene Westhovens2, Alan M. Mendelsohn3, Lilianne Kim4, Kim Hung Lo4 and Michael E. Weinblatt5, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 3Immunology, Janssen Research & Development, LLC., Spring House, PA, 4Janssen Research & Development, LLC., Spring House, PA, 5Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

      Background/Purpose: To report on sustainability and consistency of ACR component scores with intravenous (IV) golimumab (GLM) 2mg/kg+methotrexate (MTX) through wk52 in pts with active rheumatoid…
  • Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting

    Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial

    Sophine B. Krintel1, Christian Dehlendorff2, Merete Lund Hetland3, Kim Hørslev-Petersen4, Klaus K. Andersen2, Peter Junker5, Jan Pødenphant6, Torkell Ellingsen7, Palle Ahlqvist8, Hanne M. Lindegaard9, Asta Linauskas10, Annette Schlemmer11, Mette Y. Dam12, Ib Hansen13, Hans Chr Horn14, Anette Jørgensen15, Johnny Raun16, Christian G. Ammitzbøll12, Mikkel Østergaard17, Kristian Stengaard-Pedersen12 and Julia S. Johansen18, 1Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, 2Danish Cancer Society Research Center, Copenhagen, Denmark, 3DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, 4Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, 5University of Southern Denmark, Odense, Denmark, 6Copenhagen University at Gentofte, Hellerup, Denmark, 7Silkeborg Regional Hospital, Silkeborg, Denmark, 8University of Southern Denmark, Vejle, Denmark, 9Department of Rheumatology, Odense University Hospital, Odense, Denmark, 10Vendsyssel Hospital, Hjørring, Denmark, 11Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 12Arhus University Hospital, Aarhus, Denmark, 13Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 14Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, 15Rheumatology, Arhus University Hospital, Aarhus, Denmark, 16University of Southern Denmark, Graasten, Denmark, 17Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 18Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark

    Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…
  • Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting

    Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling

    Jason Ptacek1, Rachael Hawtin2, Brent Louie1, Erik Evensen1, James Cordeiro1, Barbara Mittleman1, Michelle Atallah1, Alessandra Cesano2, Clifton O. Bingham III3, Stacey Cofield4, Jeffrey R. Curtis5, Maria I. Danila4, Richard A. Furie6, MC Genovese7, Marc C. Levesque8, Larry W. Moreland8, Peter A. Nigrovic9, James R. O'Dell10, William H. Robinson11, Nancy A. Shadick9, E. William St Clair12, Christopher C. Striebich13, Geoffrey M Thiele14, Peter K. Gregersen6 and S. Louis Bridges Jr.4, 1Nodality, Inc., South San Francisco, CA, 2Nodality Inc., South San Francisco, CA, 3Rheumatology, Johns Hopkins University, Baltimore, MD, 4University of Alabama at Birmingham, Birmingham, AL, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 7Stanford University, Palo Alto, CA, 8University of Pittsburgh, Pittsburgh, PA, 9Brigham and Women's Hospital/Harvard University, Cambridge, MA, 10Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 11VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 12Medicine, Duke Unversity Medical Center, Durham, NC, 13University of Colorado Denver, Aurora, CO, 14Omaha VA and the University of Nebraska Medical Center, Omaha, NE

    Background/Purpose:   Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials.  Single cell…
  • Abstract Number: 877 • 2013 ACR/ARHP Annual Meeting

    Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis

    Charles H. Pritchard1, Maria W. Greenwald2, Joel M. Kremer3, Norman B. Gaylis4, William Rigby5, Steve Zlotnick6, Carol Chung7, Birgit Jaber8 and William Reiss9, 1Rheumatology, Drexel University College of Medicine, Willow Grove, PA, 2Desert Medical Advances, Palm Desert, CA, 3Center for Rheumatology, Albany Medical College, Albany, NY, 4Arthritis & Rheumatic Disease Specialties, Aventura, FL, 5Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, 6Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, 7Genentech Inc., South San Francisco, CA, 8F. Hoffmann-La Roche Ltd., Basel, Switzerland, 9Genentech, South San Francisco, CA

    Background/Purpose: The FDA-approved dose of rituximab (RTX) in rheumatoid arthritis (RA) is 2 × 1000 mg IV infusions given 2 weeks apart (1 course), with…
  • Abstract Number: 878 • 2013 ACR/ARHP Annual Meeting

    Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis

    Anne Sofie Siebuhr1, Anne C. Bay-Jensen1, Diana J. Leeming2, Adam Platt3, Inger Byrjalsen4, Claus Christiansen5, Désirée van de Heijde6 and Morten Asser Karsdal2, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 3Roche Products Ltd, Welwyn Garden City, United Kingdom, 4Nordic Bioscience, Herlev, Denmark, 5Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, 6Department of Rheumatology, Leiden Univerisity, Leiden, Netherlands

    Background/Purpose: As biological treatments for rheumatoid arthritis (RA) are only effective in a subpopulation of patients and the treatment can have serious side effects, there…
  • Abstract Number: 879 • 2013 ACR/ARHP Annual Meeting

    Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment

    Anne C. Bay-Jensen1, Natasja Stæhr Gudman2, Anne Sofie Siebuhr1, Claus Christiansen3 and Morten Asser Karsdal2, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized debilitating joint destruction, if not treated aggressively in the patient in most need of treatment. …
  • Abstract Number: 880 • 2013 ACR/ARHP Annual Meeting

    Role Of Urinary Podocyte Number and Urinary Podocalyxin Level As Biomarkers Of Glomerulonephritis In Systemic Lupus Erythematosus and ANCA-Associated Vasculitis

    Hiroshi Kajiyama1, Keiju Hiromura2, Daisuke Ikuma1, Hidekazu Ikeuchi2, Hiroyuki Kurosawa3, Yoshiaki Hirayama3, Fumio Gondaira3, Masanori Hara4, Yoshihisa Nojima2 and Toshihide Mimura5, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 3Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, 4Department of Pediatrics, Yoshida Hospital, Niigata, Japan, 5Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Podocytes are glomerular visceral epithelial cells functioning as molecular sieves not to allow high molecular weight protein to leak from glomerular capillary wall. The…
  • Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting

    Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is  associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus

    Nicolas Wisniacki1, Chris Stebbins2, Jadwiga Bienkowska3, Susan Gawlak2, Donald Bennett4, Yuhong Xiang5, Andrea Dearth6, Linda C. Burkly7, Ann Ranger6, Carrie Wager5, Laurence S. Magder8 and Michelle Petri9, 1Medical Research, Biogen Idec, Maidenhead, United Kingdom, 2Translational Medicine, Biogen Idec, Cambridge, MA, 3Translational Medicine, Biogen Idec Inc., Cambridge, MA, 4Biostatistics, Biogen idec, Cambridge, MA, 5Biostatistics, Biogen Idec, Cambridge, MA, 6Biogen Idec Inc, Cambridge, MA, 7Biogen Idec, Cambridge, MA, 8Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 9Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
  • Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting

    Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes

    Michelle Petri1, Laurence S. Magder2, Hong Fang1, Jadwiga Bienkowska3, Andrea Dearth4, Norm Allaire5 and Ann Ranger4, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Translational Medicine, Biogen Idec Inc., Cambridge, MA, 4Biogen Idec Inc, Cambridge, MA, 5Biogen Idec Inc., Cambridge, MA

    Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…
  • Abstract Number: 883 • 2013 ACR/ARHP Annual Meeting

    Sex Bias In Autoimmune Diseases: Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SS) Supports The Gene Dose Hypothesis

    Ke Liu1, Kenneth M. Kaufman2,3, Judith A. James4,5, Roland Jonsson6,7, Biji T. Kurien4,5,8, Xavier Mariette9, Joan T. Merrill10, Roald Omdal11, Maureen Rischmueller12,13, Timothy J. Vyse14, Marie Wahren-Herlenius15, Torsten Witte16, Christopher J. Lessard4,5, Sarah L. Zimmerman17, Susan D. Thompson18, Gideon Hirschfield19, Gang Xie20,21, Courtney G. Montgomery8,22, Wan-Fai Ng23, Gunnel Nordmark24, Patrick M. Gaffney4,8, Katherine A. Siminovitch20,25, Kathy L. Sivils4,26, Slegen (International Consortium For The Genetics Of SLE)27 and R. Hal Scofield4,5,28, 1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 2U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, 31Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 6Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 7Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, 8U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 9Paris-Sud University, Paris, France, 10Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 12Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, 13Discipline of Medicine, University of Adelaide, Adelaide, Australia, 14Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, 15Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 16Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, 17Divison of human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 18Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 19Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 20Mount Sinai Hospital, Toronto, ON, Canada, 21University Of Toronto, Toronto, ON, Canada, 22Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 23Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, 24Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 25University of Toronto, Toronto, ON, Canada, 26University of Oklahoma Health Sciences Center, Oklahoma City, OK, 27Center for Autoimmune Genomics and Etiology and Rheumatology Division, International Consortium For The Genetics Of Systemic Lupus Erythematosus, Cincinnati, OH, 28US Department of Veterans Affairs Medical Center, Oklahoma City, OK

    Background/Purpose: Female preponderance is a hallmark of most autoimmune diseases, the mechanism for which is unknown. We hypothesize that this is a consequence of a…
  • « Previous Page
  • 1
  • …
  • 2189
  • 2190
  • 2191
  • 2192
  • 2193
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology